Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients - The PREDICTIVE™ BMI clinical trial

Diabetic Medicine

Volumn 25, Issue 8, 2008, Pages 916-923

  Montañana, C Fajardo ^a   Herrero, C Hernández ^b   Fernández, M Rivas ^c  

^a HOSPITAL DE LA RIBERA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^c Hospital Infanta Luisa   (Spain)

Author keywords

Body weight; Detemir; Insulin; Obesity; Type 2 diabetes

Indexed keywords

INSULIN; INSULIN ASPART; INSULIN DETEMIR; ISOPHANE INSULIN; METFORMIN;

ADULT; AGED; ARTICLE; BEDTIME DOSAGE; BODY MASS; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

ADMINISTRATION, ORAL; AGED; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, NPH; MALE; MIDDLE AGED; OVERWEIGHT; WEIGHT GAIN;

EID: 48249139906     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2008.02483.x     Document Type: Article

References (22)

1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet 1998 352 : 837 853.
2. Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes - causes, effects and coping strategies. Diabetes Obes Metab 2007 9 : 799 812.
3. Hermansen K, Davies M. Does insulin detemir have a role in reducing risk of insulin-associated weight gain? Diabetes Obes Metab 2007 9 : 209 217.
4. Haak T, Tiengo A, Draeger E, Suntum M, Waldhäusl W. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with Type 2 diabetes. Diabetes Obes Metab 2005 7 : 56 64.
5. Raslova K, Bogoev M, Raz I, Leth G, Gall M-A, Hancu M. Insulin detemir and insulin aspart: a promising basal-bolus regimen for Type 2 diabetes. Diabetes Res Clin Pract 2004 66 : 193 201 Corrigendum. Diabetes Res Clin Pract 2006 72 : 112.
6. Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P. 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with Type 2 diabetes. Diabetes Care 2006 29 : 1269 1274.
7. Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral anti-diabetic drugs in poorly controlled Type 2 diabetes. Clin Ther 2006 28 : 1569 1581.
8. Raslová K, Tamer SC, Clauson P, Karl D. Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for Type 2 diabetes mellitus, and this advantage increases with baseline body mass index. Clin Drug Investig 2007 27 : 279 285.
9. Standl E, Lang H, Roberts A. The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of Type 1 diabetes. Diabetes Technol Ther 2004 6 : 579 588.
10. Vague P, Selam JL, Skeie S, De Leeuw I, Elte JW, Haahr H et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with Type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003 26 : 590 596.
11. De Leeuw I, Selam J-S, Skeie S, Elte JWF, Lang H, Vague P. Insulin detemir-based used in basal-bolus therapy in people with Type 1 diabetes is associated with a lower risk of nocturnal hypoglycemia and less weight gain over 12 months in comparison to NPH insulin. Diabet Obes Metab 2005 7 : 73 83.
12. Home P, Bartley P, Russell-Jones D, Hanaire-Broutin H, Heeg JE, Abrams P et al. Study to Evaluate the Administration of Insulin detemir Insulin Efficacy, Safety and Suitability (STEADINESS) Study Group. Insulin detemir offers improved glycemic control compared with NPH insulin in people with Type 1 diabetes: a randomized clinical trial. Diabetes Care 2004 27 : 1081 1087.
13. Pieber T, Draeger E, Kristensen A, Grill V. Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin. Diabet Med 2005 22 : 850 857.
14. Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with Type I diabetes mellitus using a basal-bolus regimen. Clin Ther 2004 26 : 724 736.
15. Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with Type 1 diabetes. Diabetologia 2004 47 : 622 629.
16. Dornhorst A, Lüddeke HJ, Sreenan S, Koenen C, Hansen JB, Tsur A et al. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from Type 1 and Type 2 diabetes patients in the PREDICTIVE European cohort. Int J Clin Pract 2007 61 : 523 528.
17. Riddle MC, Rosenstock J, Gerich J, Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of Type 2 diabetic patients. Diabetes Care 2003 26 : 3080 3086.
18. Fritsche A, Schweitzer, MA, Häring H-U, the 4001 Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with Type 2 diabetes. Ann Intern Med 2003 138 : 952 959.
19. Massi Benedetti M, Humburg E, Dressler A, Ziemen M. A 1-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with Type 2 diabetes. Horm Metab Res 2003 35 : 189 196.
20. Yki-Järvinen H, Kauppinen-Mäkelin R, Tiikkainen M, Vähätalo M, Virtamo H, Nikkilä K et al. Insulin glargine or NPH combined with metformin in Type 2 diabetes: the LANMET study. Diabetologia 2006 49 : 442 451.
21. Rosenstock J, Davies M, Home P, Larsen J, Tamer SC, Schernthaner G. Insulin detemir added to oral anti-diabetic drugs in Type 2 diabetes provides glycemic control comparable to insulin glargine with less weight gain. Diabetes 2006 55 : A132 (555 P).
22. Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab 2007 9 : 648 659.